Activists in the USA who support Thailand’s decision to issue compulsory licences have been highlighting data which demonstrates that the policy is proving to be highly effective in getting HIV/AIDS drugs to more patients in the country.
Essential Action's Access to Medicines Project cites data from the Thai National Health Security Office’s sub-committee for benefits and services development which gives details about the number of patients benefiting from two of the first three drugs that were compulsory licensed in late 2006 and early 2007, namely generic versions of Merck & Co’s Stocrin (efavirenz) and Abbott Laboratories’ Kaletra (lopinavir/ritonavir), both HIV/AIDS drugs.
The figures demonstrate that as of January this year, roughly 24,013 people were taking the generic version of efavirenz, approximately three times more than were using the drug before the compulsory licence is issued. Essential Action also notes that some 2,500 patients were being treated with generic lopinavir/ritonavir from India, again three times the number using the higher-priced brand-name therapy before the Thai government’s move.
Regarding the third drug, a generic version of Sanofi-Aventis/Bristol-Myers Squibb’s antiplatelet blockbuster Plavix (clopidogrel) has already registered by the GPO. It is produced by India’s Cadila Healthcare, and an order of the first batch for two million tablets was placed.
Since then, four other compulsory licences have been issued on cancer drugs –Sanofi’s Taxotere (docetaxel), Roche/Genentech’s Tarceva (erlotinib) and Novartis’ Femara (letrozole) and Glivec/Gleevec (imatinib), though the latter licence was cancelled after the Swiss firm agreed to supply it free to hundreds of leukemia patients in Thailand. The new government in Bangkok has suggested that it intends to continue with the policy, a move that has given rise to fears that the USA and the European Union will step up pressure on the Thais to think again.
